troglitazone has been researched along with Drug Hypersensitivity in 2 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Drug Hypersensitivity: Immunologically mediated adverse reactions to medicinal substances used legally or illegally.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Troglitazone was the first thiazolidinedione antidiabetic agent approved for clinical use in 1997, but it was withdrawn from the market in 2000 due to serious idiosyncratic hepatotoxicity." | 2.46 | Troglitazone. ( Yokoi, T, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yokoi, T | 1 |
| Ikeda, T | 1 |
2 reviews available for troglitazone and Drug Hypersensitivity
| Article | Year |
|---|---|
Troglitazone.
Topics: Biotransformation; Chemical and Drug Induced Liver Injury; Chromans; Drug Hypersensitivity; Humans; | 2010 |
[Drug-induced liver injury].
Topics: Acetaminophen; Anesthetics, General; Animals; Benzoquinones; Chemical and Drug Induced Liver Injury; | 2006 |